Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
-
Published:2024-02
Issue:
Volume:73
Page:103612
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Bao Kelvin KH.ORCID,
Chan Jeffrey CH.,
Chan Jocelyn G.,
Sutanto Leone,
Cheung Ka Man,
Yiu Harry HY.
Subject
General Medicine,Surgery
Reference9 articles.
1. Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020
2. Real-world evidence of trastuzumab, pertuzumab, and docetaxel combination as a first-line treatment for Korean patients with HER2-positive metastatic breast cancer;Lee;Cancer Res Treat,2022
3. Cardiac surveillance for anti-HER2 chemotherapy;Collier;Cleve Clin J Med,2021
4. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
5. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?;Bouwer;Breast Cancer Res Treat,2021